MacroGenics, Inc.
 (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with 

Janssen Biotech, Inc.
 The research collaboration will incorporate 

 proprietary DART® platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology.

“We are excited to collaborate with Janssen, which we believe is a leader in the field of next generation antibody-based therapeutics, by bringing together our two companies’ respective scientific talent and experience to leverage our DART platform to generate a compelling product candidate that addresses unmet patient needs,” said  Scott Koenig , M.D., Ph.D., President and Chief Executive Officer of 


Under the terms of the agreement, Janssen will pay 

 an upfront payment of 

$20 million
 and will be responsible for funding all expenses. 

 will also be eligible to receive up to 

$312 million
 in potential milestone payments and tiered royalties on worldwide product sales. Further details about the transaction are not disclosed.

Read the full article at: